期刊
LEUKEMIA & LYMPHOMA
卷 54, 期 2, 页码 255-260出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2012.715350
关键词
Chimeric antigen receptor; CD19; adoptive immunotherapy; leukemia; lymphoma
资金
- National Natural Science Foundation of China [30971283, 81170502, 31100638]
- Zhejiang Provincial Natural Science Foundation of China [Y2110020]
- PhD Programs Foundation of the Ministry of Education of China [20110101120138]
There remain some key questions regarding the adoptive infusion of chimeric antigen receptor (CAR) transduced T-cells in the clinical setting. This article systematically reviews the phase I clinical trials using CARs targeting CD19 in B-lineage malignancies. Twenty-nine patients were enrolled and the 6-month progression free survival for this cohort was 50.0 +/- 9.9%. Univariate analysis showed that patients benefited from lymphodepletion before CAR+ T-cell infusion and the administration of interleukin-2 (IL-2). Longer-term persistence (>= 4 weeks) and stronger expansion of CAR+ T-cells in the blood and higher peak serum interferon-gamma (IFN-gamma) level (>= 200 pg/mL) were also related to superior outcome. Regarding treatment-related adverse events, the most prominent toxicities were fever, rigors, chills, acute renal failure, hypotension and capillary leak syndrome. In conclusion, anti-CD19 CAR+ T-cells have shown some benefits in patients with B-lineage malignancies and are well tolerated in most patients. Preconditioning and cytokine supplement are required to improve the clinical outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据